Differences in lipid measurements by antiretroviral regimen exposure in cohorts from Asia and Australia

AIDS Research and Treatment

Volumn 2012, Issue , 2012, Pages

  Achhra, Amit C ^a   Amin, Janaki ^a   Hoy, Jennifer ^b   Tanuma, Junko ^c   Sirisanthana, Thira ^d   Nolan, David ^e   Merati, Tuti ^f   Giles, Michelle ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ALFRED HOSPITAL   (Australia)

^c NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^d CHIANG MAI UNIVERSITY   (Thailand)

^e ROYAL PERTH HOSPITAL   (Australia)

^f UDAYANA UNIVERSITY   (Indonesia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84873819162     PISSN: 20901240     EISSN: 20901259     Source Type: Journal    
DOI: 10.1155/2012/246280     Document Type: Article

References (23)

1. Fichtenbaum C. J., Metabolic abnormalities associated with HIV infection and antiretroviral therapy. Current Infectious Disease Reports 2009 11 1 84 92 2-s2.0-67649403401 10.1007/s11908-009-0012-8
2. Fontas E., Van Leth F., Sabin C. A., Friis-Møller N., Rickenbach M., D'Arminio Monforte A., Kirk O., Dupon M., Morfeldt L., Mateu S., Petoumenos K., El-Sadr W., De Wit S., Lundgren J. D., Pradier C., Reiss P., Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? Journal of Infectious Diseases 2004 189 6 1056 1074 2-s2.0-12144286934 10.1086/381783 (Pubitemid 38373099)
3. Mallon P. W. G., Antiretroviral therapy-induced lipid alterations: in-vitro, animal and human studies. Current Opinion in HIV and AIDS 2007 2 4 282 292 2-s2.0-34250639736 10.1097/COH.0b013e3281e72ca0 (Pubitemid 46941820)
4. Riddler S. A., Li X., Chu H., Kingsley L. A., Dobs A., Evans R., Palella F., Visscher B., Chmiel J. S., Sharrett A. R., Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy. HIV Medicine 2007 8 5 280 287 2-s2.0-34250204094 10.1111/j.1468-1293.2007.00470.x (Pubitemid 46901526)
5. Hill A., Sawyer W., Gazzard B., Effects of first-line use of nucleoside analogues, efavirenz, and ritonavir-boosted protease inhibitors on lipid levels. HIV Clinical Trials 2009 10 1 1 12 2-s2.0-64949092835 10.1310/hct1001-001
6. Van Leth F., Phanuphak P., Stroes E., Gazzard B., Cahn P., Raffi F., Wood R., Bloch M., Katlama C., Kastelein J. J. P., Schechter M., Murphy R. L., Horban A., Hall D. B., Lange J. M. A., Reiss P., Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. Plos Medicine 2004 1 1, article no. e19 064 074 2-s2.0-15744367156 10.1371/journal.pmed.0010019
7. Carey D., Amin J., Boyd M., Petoumenos K., Emery S., Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials. Journal of Antimicrobial Chemotherapy 2010 65 9 1878 1888 2-s2.0-77955622847 10.1093/jac/dkq231 dkq231
8. Crane H. M., Grunfeld C., Willig J. H., Mugavero M. J., Van Rompaey S., Moore R., Rodriguez B., Feldman B. J., Lederman M. M., Saag M. S., Kitahata M. M., Impact of nrtis on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care. AIDS 2011 25 2 185 195 2-s2.0-78650902667 10.1097/QAD.0b013e328341f925
9. World Health Organisation, Transaction prices for Antiretroviral Medicines and HIV Diagnostics from 2008 to March 2010. 2010
10. World Health Organisation, Prioritizing Second-Line Antiretroviral Drugs for Adults and Adolescents: a Public Health Approach. 2007
11. Foulkes A. S., Wohl D. A., Frank I., Puleo E., Restine S., Wolfe M. L., Dube M. P., Tebas P., Reilly M. P., Associations among race/ethnicity, apoc-iii genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy. Plos Medicine 2006 3 3, e52 337 347 2-s2.0-33645329876 10.1371/journal.pmed. 0030052
12. Míguez-Burbano M. J., Lewis J. E., Malow R., Alcohol and race/ethnicity elicit different changes in lipid profiles in HIV-infected individuals receiving highly active antiretroviral therapy. Journal of the Association of Nurses in AIDS Care 2009 20 3 176 183 2-s2.0-65449188336 10.1016/j.jana.2009.02.004
13. Shephard R. J., Cox M., West C., Some factors influencing serum lipid levels in a working population. Atherosclerosis 1980 35 3 287 300 2-s2.0-0018838591 (Pubitemid 10174127)
14. Achhra A. C., Zhou J., Choi J. Y., Hoy J., Zhang F., Templeton D. J., Merati T., Woolley I., Petoumenos K., Amin J., The clinical significance of cd4 counts in asian and caucasian HIV-infected populations: results from tahod and ahod. Journal of the International Association of Physicians in AIDS Care 2011 10 3 160 170 2-s2.0-79957442409 10.1177/1545109711402213
15. Australian HIV Observational Database, Rates of combination antiretroviral treatment change in Australia. HIV Medicine 2002 3 28 36
16. Zhou J., Kumarasamy N., Ditangco R., Kamarulzaman A., Lee C. K. C., Li P. C. K., Paton N. I., Phanuphak P., Pujari S., Vibhagool A., Wong W. W., Zhang F., Chuah J., Frost K. R., Cooper D. A., Law M. G., The treat asia HIV observational database: baseline and retrospective data. Journal of Acquired Immune Deficiency Syndromes 2005 38 2 174 179 2-s2.0-19944433996 10.1097/01.qai.0000145351.96815.d5 (Pubitemid 40189324)
17. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recommendations and Reports 1992 41 1 19
18. Kerr S. J., Duncombe C., Avihingsanon A., Ananworanich J., Boyd M., Sopa B., Medtech B., Chuenyam T., Cooper D. A., Lange J. M., Phanuphak P., Ruxrungtham K., Dyslipidemia in an asian population after treatment for two years with protease inhibitor-containing regimens. Journal of the International Association of Physicians in AIDS Care 2007 6 1 36 46 2-s2.0-34248563006 10.1177/1545109706295946
19. Padmapriyadarsini C., Kumar S. R., Terrin N., Narendran G., Menon P. A., Ramachandran G., Subramanyan S., Venkatesan P., Wanke C., Swaminathan S., Dyslipidemia among HIV-infected patients with tuberculosis taking once-daily nonnucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in india. Clinical Infectious Diseases 2011 52 4 540 546 2-s2.0-79951824946 10.1093/cid/ciq195
20. Morris A., Ferdinand K. C., Hyperlipidemia in racial/ethnic minorities: differences in lipid profiles and the impact of statin therapy. Clinical Lipidology 2009 4 6 741 754 2-s2.0-77649089072 10.2217/clp.09.70
21. Friis-Moller N., Thiebaut R., Reiss P., Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. European Journal of Cardiovascular Prevention & Rehabilitation 2010 17 491 501
22. Schambelan M., Wilson P. W. F., Yarasheski K. E., Cade W. T., Davila-Roman V. G., D'Agostino R. B., Helmy T. A., Law M., Mondy K. E., Nachman S., Peterson L. R., Worm S. W., Development of appropriate coronary heart disease risk prediction models in HIV-infected patients. Circulation 2008 118 2 e48 e53 2-s2.0-47649109545 10.1161/CIRCULATIONAHA.107.189627
23. Worm S. W., Kamara D. A., Reiss P., Kirk O., El-Sadr W., Fux C., Fontas E., Phillips A., D'Arminio Monforte A., De Wit S., Petoumenos K., Friis-Møller N., Mercie P., Lundgren J. D., Sabin C., Elevated triglycerides and risk of myocardial infarction in HIV-positive persons. AIDS 2011 25 12 1497 1504 2-s2.0-79960564501 10.1097/QAD.0b013e32834917c6